Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.
Zoledronate, a potent third-generation amino-bisphosphonate previously used for the treatment of bone metastasis, was recently shown to significantly reduce the risk of vertebral and hip fractures in osteoporotic postmenopausal women when infused at a dose of 5 mg per year for 3 years. The renal follow-up of this pivotal study that included more than 5,000 patients (estimated creatinine clearance >30 ml per min) is reported by Boonen et al. and shows the long-term renal safety of zoledronate in this osteoporotic population.
Lafage-Proust
Marie-Hélène
MH
Institut National de la Santé et de la Recherche Medicale, Unité 890, Université Jean Monnet, Centre Hospitalier Universitaire, Saint-Etienne, France. lafagemh@univ-st-etienne.fr
D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D003404:Creatinine / Q000378:metabolism; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects* / Q000502:physiology; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D012449:Safety; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D003404:Creatinine